DDInter1340 DDInter1435
Originally approved by the FDA in 1989, omeprazole is a _proton-pump inhibitor_, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class, and its approval was followed by the formulation of many other proton pump inhibitor drugs. Omeprazole is generally effective and well-tolerated, promoting its popular use in children and adults [FDA label].
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Omeprazole {u} (Compound) resembles {v} (Compound) Pantoprazole
Omeprazole {u} (Compound) resembles {v} (Compound) Esomeprazole
Omeprazole {u} (Compound) treats {v} (Disease) Barrett's esophagus
Omeprazole {u} (Compound) binds {v} (Gene) CYP1A2
Omeprazole {u} (Compound) upregulates {v} (Gene) TIPARP
Omeprazole {u} (Compound) palliates {v} (Disease) systemic scleroderma
Omeprazole {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C19 Inhibitors
Omeprazole {u} (Compound) downregulates {v} (Gene) THAP11
Omeprazole {u} (Compound) causes {v} (Side Effect) Alanine aminotransferase increased
Omeprazole (Compound) resembles Pantoprazole (Compound)
Omeprazole (Compound) resembles Esomeprazole (Compound)
Omeprazole (Compound) treats Barrett's esophagus (Disease)
Omeprazole (Compound) binds CYP1A2 (Gene)
Omeprazole (Compound) upregulates TIPARP (Gene)
Omeprazole (Compound) palliates systemic scleroderma (Disease)
Omeprazole (Compound) is included by Cytochrome P450 2C19 Inhibitors (Pharmacologic Class)
Omeprazole (Compound) downregulates THAP11 (Gene)
Omeprazole (Compound) causes Alanine aminotransferase increased (Side Effect)